A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples